To support our commitment to DM research, MDF awards fellowship grants to postdoctoral researchers as part of our annual Fund-A-Fellow (FAF) program. We recently caught up with one of our current grant recipients, Dr. Nicholas Johnson, Assistant Professor of Neurology at the University of Utah.
At the 2013 MDF conference, Dr. Tom Cooper of Baylor College of Medicine presented a summary of the ninth meeting of the International Myotonic Dystrophy Consortium (IDMC).
Researchers have published several recent studies on advances in DM research.
Ionis Pharmaceuticals (formerly Isis Pharmaceuticals, Inc.) announced the identification of a drug development candidate, IONIS-DMPKRx, designed to treat Myotonic Dystrophy Type 1 (DM1), which they plan to advance into human clinical trials next year.
Timeline of key discoveries in myotonic dystrophy research since DM was first described in 1909.